CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for CymaBay Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CymaBay Therapeutics Inc
SUITE 130, 7999 GATEWAY BLVD
Phone: (510) 293-8800p:510 293-8800 NEWARK, CA  94560  United States Fax: (510) 293-9090f:510 293-9090
This company was Merged or Acquired on 3/22/2024.
This company ceased filing statements with the SEC on 4/1/2024.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar (MBX-8025), is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The Company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Robert J.Wills 69 10/8/2015 3/18/2015
President, Chief Executive Officer, Director Sujal A.Shah 49 1/1/2020 12/6/2013
Chief Financial Officer HarishShantharam 43 5/22/2023 5/22/2023
8 additional Officers and Directors records available in full report.

Business Names
Business Name
CymaBay Canada, Ltd.
CymaBay Ireland, Limited
CymaBay Therapeutics Inc
CymaBay UK, Ltd.
Metabolex, Inc.

General Information
Number of Employees: 108 (As of 1/31/2024)
Outstanding Shares: 114,785,001 (As of 2/9/2024)
Shareholders: 172
Stock Exchange: NASD
Federal Tax Id: 943103561
Fax Number: (510) 293-9090
Email Address: info@cymabay.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024